What retatrutide is
Retatrutide is a once-weekly injectable peptide developed by Eli Lilly. It is a triple agonist: a single molecule that activates three hormone receptors involved in appetite and metabolism:
| Receptor | Main effects relevant to weight |
|---|---|
| GLP-1 (glucagon-like peptide-1) | Reduces appetite and slows stomach emptying; the target of semaglutide |
| GIP (glucose-dependent insulinotropic polypeptide) | Adds to GLP-1's effects on appetite and blood sugar; tirzepatide targets GIP and GLP-1 |
| Glucagon | May increase energy expenditure and affect liver fat |
Adding glucagon receptor activity to the GIP and GLP-1 combination is what distinguishes retatrutide from approved incretin drugs.
Clinical evidence
Phase 2
In a 48-week Phase 2 trial of 338 adults with obesity, published in the New England Journal of Medicine in 2023, weight loss increased with dose:
| Dose | Change in body weight at 48 weeks |
|---|---|
| 1 mg | −8.7% |
| 4 mg (combined groups) | −17.1% |
| 8 mg (combined groups) | −22.8% |
| 12 mg | −24.2% |
| Placebo | −2.1% |
At 48 weeks, 83% of participants on 12 mg had lost at least 15% of their body weight, compared with 2% on placebo. The most common adverse events were gastrointestinal. These were dose-related and mostly mild to moderate, and a lower starting dose partly reduced them. Heart rate rose with dose, peaked at 24 weeks, and declined thereafter.
Phase 3: the TRIUMPH program
Lilly's Phase 3 obesity program, TRIUMPH, includes several large trials. ClinicalTrials.gov lists TRIUMPH-1 (2,335 participants), TRIUMPH-2 (type 2 diabetes), TRIUMPH-3 (cardiovascular disease), and TRIUMPH-4 (knee osteoarthritis) as complete.
On May 21, 2026, Lilly reported that in TRIUMPH-1, participants taking the 12 mg dose lost an average of 28.3% of body weight over 80 weeks. This is a company-reported topline figure. Full peer-reviewed results will allow the effect to be compared across analysis methods and against placebo in detail.
In its August 2026 quarterly report, filed with the SEC, Lilly stated that "the clinical data package is now complete to support global registrations for obesity," with plans to submit a Biologics License Application to the FDA in the first quarter of 2027. In October 2026, Lilly reported positive topline results from a head-to-head Phase 3 trial of retatrutide versus semaglutide (Ozempic 2 mg) in type 2 diabetes.
Scientific perspective
Retatrutide's Phase 2 and reported Phase 3 results place it among the most effective weight-loss medicines ever tested. The scientific questions now concern how the effect is achieved and at what cost:
- Tolerability. Gastrointestinal effects are common to the whole drug class. Whether the highest doses are tolerable for long-term use is central to how widely the drug would be used.
- Heart rate. Phase 2 showed dose-dependent heart-rate increases that later declined. Long-term cardiovascular safety will be assessed in the dedicated outcomes trial.
- Body composition. With very large weight loss, the proportion of lean tissue lost, and its consequences, is an active research question for the class.
- Durability. As with other incretin drugs, weight regain after stopping is likely. A maintenance trial, TRIUMPH-6, is listed as active.
Development perspective
- Regulatory status: not approved by the FDA or, to our knowledge, any regulator. openFDA lists no application record.
- Next milestone: BLA submission, planned for Q1 2027 (company-reported). The FDA's standard review goal for a new molecular entity is 10 months after its 60-day filing period, or about 12 months from submission. See How Does the FDA Approve New Drugs?
- Historical benchmark: programs that have reached Phase 3 have historically had about a 52% chance of eventual approval. Retatrutide's completed Phase 3 obesity trials and reported results put it in a stronger position than an average Phase 3 program, but benchmarks do not adjust for drug-specific evidence.
- Illegal products: Lilly has publicly called on online platforms, payment companies, and regulators to shut down what it calls an illegal retatrutide black market (October 2026 SEC filing). Products sold as "retatrutide" outside clinical trials are not approved and have not been evaluated for quality or safety.
Competitive context
Retatrutide would enter a market led by Lilly's own tirzepatide (Zepbound, Mounjaro) and Novo Nordisk's semaglutide, alongside Lilly's oral GLP-1 drug orforglipron (Foundayo). Its potential advantage is greater weight loss. Its challenges will be tolerability, pricing, and showing benefits beyond weight, which Lilly is studying in osteoarthritis, sleep apnea, kidney, and cardiovascular outcomes trials.
Development timeline
- May 20, 2021Phase 2 obesity trial begins (338 participants). Registry
- Jun 26, 2023Phase 2 results published: −24.2% body weight at 48 weeks on 12 mg, versus −2.1% with placebo. Peer-reviewed
- Jul 10, 2023TRIUMPH-1 Phase 3 obesity trial begins. Registry
- Apr 30, 2024Cardiovascular and kidney outcomes trial begins (estimated 10,000 participants). Registry
- May 21, 2026Lilly reports TRIUMPH-1 topline results: average weight loss of 28.3% at 80 weeks on 12 mg. Company-reported
- Aug 5, 2026Lilly states the data package is complete to support global registrations for obesity, with plans to submit a BLA to the FDA in Q1 2027. Company-reported
- Oct 29, 2026Lilly reports positive topline results from a head-to-head Phase 3 trial of retatrutide versus Ozempic 2 mg. Company-reported
What could change the outlook
- Submission of the Biologics License Application, which Lilly plans for Q1 2027, and FDA acceptance for review.
- Peer-reviewed publication of the full TRIUMPH results, including safety and tolerability details beyond the topline releases.
- Tolerability at the highest doses: gastrointestinal effects and heart-rate increases were dose-related in Phase 2.
- Results of the 10,000-participant cardiovascular and kidney outcomes trial (registry estimates primary completion in February 2029).
- Head-to-head data against tirzepatide (TRIUMPH-5, active per the registry).
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Retatrutide. Company-reported, not independently verified.
- Quarterly reportCompany-reportedOct 29, 2026
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
“Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.
- Trial resultsCompany-reportedOct 28, 2026
Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
Eli Lilly and Company (NYSE: LLY ), the maker of Mounjaro (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes.
- Trial resultsCompany-reportedSep 29, 2026
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1 , and glucagon triple hormone receptor agonist, in...